Avicanna Inc has experienced significant volatility in its stock performance recently, with a notable decrease over the past week.
This week, Avicanna Inc (TSX: AVCN) closed at C$0.10, reflecting a steady decline of 12.50% over the past week and a staggering 52.27% drop year-to-date. Despite recent developments in the cannabis sector, the stock has faced challenges that investors should consider.
Advertisement
Avicanna Inc
AVCN.TO
AVCN.TO
Avicanna Inc
WealthAwesomeMarket cap
$14.11M
52W high
$0.30
52W low
$0.10
1W change
-12.50%
Beta
0.34
Analyst Price Targets
Based on analyst covering AVCN · as of Sep 17, 2026
Wall Street analysts forecast AVCN stock price to rise 566.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.70
+566.7% Upside
Current Price
C$0.10
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on AVCN's historical volatility
30-Day Vol
93.1%
Annualized
90-Day Vol
80.7%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.09
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.10 | C$0.07 – C$0.14 |
| 60 trading days | C$0.09 | C$0.06 – C$0.15 |
| 90 trading days | C$0.09 | C$0.05 – C$0.15 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors in Avicanna should be aware of the company's recent initiatives and the broader market context, particularly as it continues to navigate a challenging financial landscape.
Avicanna's stock has plummeted 52.27% YTD, closing at C$0.10.
Despite a bullish average analyst target of C$0.70, Avicanna's recent performance raises questions about its current valuation and market position.
Bull case
The launch of the MyMedi.ca Integrated Healthcare Program and positive analyst outlooks could signal growth potential for Avicanna in the evolving cannabis market. This initiative aims to enhance access to medical cannabis care across Canadian healthcare institutions, aligning with the growing acceptance of cannabis in healthcare. Additionally, the recent decision by the U.S. Department of Justice to reschedule certain cannabinoid-based products may support Avicanna's pharmaceutical strategy.
Bear case
Ongoing losses and a significant decline in stock price could deter investors, especially in light of the recent performance metrics and market cap. The stock is currently trading below its 50-day moving average of C$0.13 and its 200-day moving average of C$0.16, indicating a bearish trend. With a 52-week range of C$0.10 to C$0.30, the current price sits at the lower end of this spectrum. The beta of 0.34 suggests lower volatility compared to the broader market, but the recent trading volume of 16,300 shares is significantly below the 20-day average volume of 153,264 shares, indicating reduced investor interest.
Advertisement
Recent Price Action
Avicanna Inc (AVCN.TO) has closed at C$0.10, marking a 1-day change of 0.00%. Over the past week, the stock has seen a decline of 12.50%, alongside a more significant drop of 19.23% in the past month. Year-to-date, the stock is down 52.27%, reflecting ongoing challenges in the company's operational and financial performance.
Company News and Developments
While there has been no major news this week, Avicanna recently launched the MyMedi.ca Integrated Healthcare Program, aiming to enhance access to medical cannabis care across Canadian healthcare institutions. This initiative, introduced on September 9, 2026, could potentially improve the company's market presence as it aligns with the growing acceptance of cannabis in healthcare. Furthermore, the company welcomed the U.S. Department of Justice's decision to reschedule certain cannabinoid-based products, which may support its pharmaceutical strategy.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
